FIGURE 6.

KS18 increases the efficacies of Bcl-2/Bcl-xL inhibitors in bortezomib resistant cells. (A, B), U266-BTZ-R cells were subjected to treatment with venetoclax (VEN) at concentrations of 1 and 2.5 μM, or ABT-737 (ABT) at the same concentrations, both alone and in conjunction with KS18 (5 μM) for a duration of 24 h and immunoblotting was conducted to assess the specified anti-apoptotic proteins. (C–E), U266-BTZ-R cells were subjected to a 24-h treatment with KS18 (5 μM) either alone or in conjunction with VEN (5 µM), cyclophosphamide (CP) (5 µM), doxorubicin (DOX) (1 µM), and dexamethasone (DEX) (1 µM), subsequently stained with Annexin V dye and evaluated using the Muse Cell Analyzer. The total count of apoptotic cells was quantified (n = 3), and one-way ANOVA was conducted, and graph was generated utilizing GraphPad Prism software. Vehicle treated cells served as control in all experiments. ****P < 0.0001.